HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Next US FDA Commissioner Will Have Opening To Fill In Dietary Supplement Programs Office

Executive Summary

Steven Tave on 15 March will move from ODSP director to lead ORA’s Office of Strategic Planning and Operational Policy. Agency’s next commissioner, who Capitol Hill lobbyists say could be named next week, will appoint a replacement.

You may also be interested in...



Dietary Ingredient Advisory List Yet To Fulfill Potential For US FDA

"We haven't utilized the ingredient advisory list quite as much as I'd like to see. But it's something we'll be working on this year,” says Cara Welch, acting director of FDA’s Office of Dietary Supplement Programs.

US Rule For Mandatory Supplement Registration Would Likely Give FDA Authority For Fines

“We would certainly want to have some enforcement and be able to utilize that enforcement,” says ODSP acting director Cara Welch. Stakeholders opposed to the change should “get comfortable with the idea of opening up DSHEA and should most certainly be part of the discussion.”

Third-Party Assistance On US FDA’s Plate For Cutting Backlog Of Supplement Facility Inspections

“We had a good chunk of time when our investigators were not able to go out and get into facilities in a safe manner,” says Cara Welch, acting director of FDA Office of Dietary Supplement Programs. “I absolutely agree on starting the conversation for third-party inspections,” she adds.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel